Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier
Executive Summary
Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.
You may also be interested in...
Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount
Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.
Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount
Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.